Compare Sanofi SA (SNY) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs ProShares Ultra Semiconductors — how do they compare? Sanofi SA trades at $43.51 (market cap $104.30B), while ProShares Ultra Semiconductors trades at $91.94. The key difference: Sanofi SA pays a 5.55% dividend while ProShares Ultra Semiconductors pays none, and ProShares Ultra Semiconductors is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| SNY | USD | |
|---|---|---|
Market Cap | $104.30B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $52.34 | $113.53 |
52-Week Low | $41.33 | $40.97 |
Enterprise Value | $124.19B | — |
Dividend Yield | 5.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
USD stock trades at $93.67, up 3.46% in the past 24 hours, with technical indicators signaling a bullish trend. The stock shows strong momentum above key support levels, though the RSI_6 at 99.69 suggests overbought conditions. A dividend of $0.14 is scheduled for June 30, 2026. Recent news highlights corporate developments in financial services and technology sectors.
The outlook remains positive given bullish technical signals and corporate actions, but high RSI indicates potential near-term pullback risks. Investors should weigh the dividend yield against valuation concerns amid limited fundamental data availability. Market sentiment is mixed, with institutional interest balanced by overbought technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
